HOME > BUSINESS
BUSINESS
- Amgen Plans New Product Debuts in Japan by 2016, Pins Hopes on Hyperlipidemia Drug
April 10, 2013
- Trazenta Now Stands at Starting Line Without Concurrent Use Restrictions: NBI President Aono
April 10, 2013
- DSP to Solely Develop Therapeutic Cancer Vaccines, Terminating Joint Development Agreement with Chugai
April 10, 2013
- Teva Japan: Pres. Shimada to Retire, Eli Lilly’s Kikushige to Take Helm
April 9, 2013
- Kowa, Daiichi Sankyo to End Livalo, Olmetec Marketing Partnership in June
April 9, 2013
- Eisai Sets Up Sales Subsidiary in Russia
April 9, 2013
- Ajinomoto Acquires US-Based Althea Technologies to Expand Biotech Operations
April 9, 2013
- Rubella Epidemic Triggers Vaccine Shipment Adjustments at Drug Makers
April 9, 2013
- Astellas Collaborates with Ambrx for Discovery and Development of Novel ADCs for Oncology Fields
April 9, 2013
- Novo Nordisk’s FY2012 Sales Dip 0.8% with Insulin Market Subdued by DPP-4 Inhibitors
April 8, 2013
- Abbott Japan Sales Decline 3.2% in 2012 Due to Product Transfer to AbbVie
April 8, 2013
- Survey by JCSOA Finds Big Increase in Use of CMRs to Detail Long-Listed and Non-Priority Products
April 8, 2013
- Teijin Acquires 10% Stake in Kyorin for Strategic Alliance
April 8, 2013
- Bell Medical Solutions Concludes Business Alliance Agreement for CRO Business with inVentiv Health Clinical
April 8, 2013
- Allegra Generic Versions Expected to Be Further Promoted: Pharmacist Survey
April 5, 2013
- Takeda to Successively File 2 New Diabetes Drugs in Japan
April 5, 2013
- MPD Begins Marketing BindRen in Germany and Austria
April 5, 2013
- Daiichi Sankyo Ends ATK Inhibitor Agreement with ArQule
April 5, 2013
- AnGes to Acquire Exclusive Rights for CIN Therapeutic Vaccine for Cervical Precancerous Lesions in Major Countries
April 5, 2013
- MTPC Agrees to Transfer Tanabe Europe Shares to API in Tokyo
April 4, 2013
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…